NAT10 and neoplasm: The tumor tissues were subsequently investigated using H&E staining and Ki-67 immunohistochemical analysis, which showed that NAT10 knockdown significantly increased the therapeutic efficacy of gefitinib and Osimertinib (Fig. 3G).